Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma Journal Article


Authors: Ratner, L.; Rauch, D.; Abel, H.; Caruso, B.; Noy, A.; Barta, S. K.; Parekh, S.; Ramos, J. C.; Ambinder, R.; Phillips, A.; Harding, J.; Baydoun, H. H.; Cheng, X.; Jacobson, S.
Article Title: Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma
Keywords: treatment outcome; genetics; prednisone; mortality; doxorubicin; antineoplastic agent; bortezomib; etoposide; antineoplastic combined chemotherapy protocols; cyclophosphamide; vincristine; virology; htlv-i infections; human t-lymphotropic virus 1; leukemia-lymphoma, adult t-cell; complication; humans; human; raltegravir; htlv-1 infection; raltegravir potassium
Journal Title: Blood Cancer Journal
Volume: 6
ISSN: 2044-5385
Publisher: Nature Publishing Group  
Date Published: 2016-03-25
Start Page: e408
Language: English
DOI: 10.1038/bcj.2016.21
PUBMED: 27015285
PROVIDER: scopus
PMCID: PMC4817103
DOI/URL:
Notes: Letter -- Export Date: 3 April 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Ariela Noy
    206 Noy